March 7, 2025
Downloadable PDF: Prepared on Paper: Lassa in the Heartland
January 24, 2025
Downloadable PDF: Communication Strategies for Frontline Workers in Times of Crisis
November 22, 2024
Downloadable PDF: Mpox: Forgotten but not Gone
Downloadable PDF: Best Practices in Blood Resuscitation for Acute Trauma and in Disasters
June 14, 2024
Downloadable PDF: A Discussion on H5N1 Avian Flu
Q&A Forum from this Webinar
with Dr. Tim Uyeki
Q: Can you clarify the information on wastewater surveillance? Does it reflect human sources or both animal and human sources for influenza. How will you tell the difference if disease is asymptomatic?
A: Wastewater surveillance that detects influenza A viruses cannot distinguish detection of seasonal influenza A virus infections of humans from influenza A virus infections of animals (wild birds, poultry, pigs, cows, cow milk, other infected mammals). Wastewater surveillance that detects A(H5) cannot distinguish detection of A(H5) viruses from infected animals or cow milk or a few human infections and cannot identify the source, so any signal needs to be investigated. There are poultry outbreaks of H5N1, wild bird detections, and H5N1 viruses are highly concentrated in the raw milk of infected cows.
Wastewater surveillance is only one component of a bundle of influenza surveillance platforms and tools.
Q: Any ideas on conducting human challenge studies on H5 vaccines for efficacy?
A: This has not been done. H5N1 virus challenge studies in vaccinated animal models (mice, ferrets) have been used.
Q: Since we see alpha 2,3 receptors in human conjunctiva do you think this could serve as a viable conduit to the mutations mentioned needed to overcome the alpha 2,6 receptor difference.
A: Yes, H5N1 viruses can infect conjunctival tissues because conjunctival tissues have abundant alpha 2,3 sialic acid linked receptors; virus can potentially enter the upper respiratory tract via the nasolacrimal duct and might establish infection because there are some alpha 2,3 receptors in the upper respiratory tract – it is not 100% alpha 2,6 receptor distribution. That might not result in a receptor tropism switch, however. The main issue is that H5N1 viruses need to establish infection in the lower respiratory tract where alpha 2,3 receptors are most prevalent.
Downloadable PDF: Behavioral Health in Disaster Response
April 26, 2024
Downloadable PDF: Pediatric Readiness: Critical Steps in Pediatric Disaster Preparedness
March 29, 2024
Downloadable PDF: Cyberattacks and the Healthcare System
February 28, 2024
January 26, 2024
December 8, 2023
October 30, 2023
October 23, 2023
August 11, 2023
Downloadable PDF: Emerging Special Pathogens (Including Avian Influenza), The Importance of Identify/Isolate/Inform
April 14, 2023
Downloadable PDF: Family Reunification Following Disaster: Planning for Considerations and Tools for Healthcare Facilities
March 30, 2023
Downloadable PDF: Surging Hospital ICU Capacities: Lessons Learned from COVID and RSV
Downloadable PDF: Ugandan Response to the 2022 Ebola Outbreak: Perspectives and Lessons Learned
December 21, 2022
Downloadable PDF: Disposition: Clinical Decision Making in Pediatric Respiratory Illness
December 20, 2022
Downloadable PDF: Fever in the Returning Traveler
December 14, 2022
Downloadable PDF: Interim Management of the Patient with Respiratory Illness Awaiting Transfer
December 7, 2022
Downloadable PDF: Pediatric Intubation
November 30, 2022
Downloadable PDF: Providing Non-Invasive Ventilation (NIV) for Pediatric Patients
November 23, 2022
Downloadable PDF: High Flow Nasal Cannula Therapy for Bronchiolitis: Managing Pediatric HFNC Outside the ICU
November 17, 2022
Downloadable PDF: Assessment and Management of the Pediatric Patient with Acute Respiratory Illness
Downloadable PDF: Updates on the Ebola Virus Disease Outbreak in Uganda and Preparedness Planning
Downloadable PDF: Navigating Legalities in CSC Webinar 12-15-21
Downloadable PDF: Changes in the Legal Landscape Post-COVID-19 Webinar 6-8-21
Downloadable PDF: Healthcare Worker Wellbeing and Resiliency Webinar 3-30-21
Downloadable PDF: COVID-19 Monoclonal Antibody Therapies Regional RDHRS Webinar 12-15-20
Downloadable PDF: COVID-19 Treatments Update Webinar 11-06-20